Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › avacopan

avacopan

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of avacopan

4 trials tracked of avacopan: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 988 citations.

4Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2 Phase 1 1
  1. Phase 3 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Completed · 988 cited
  2. Phase 2 Controlled Trial Evaluating Avacopan in C3 Glomerulopathy Completed
  3. Phase 2 Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) Completed
  4. Phase 1 A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Avacopan is associated with high remission rates and low relapse in ANCA-associated vasculitis
Rheumatology Sys. Review
Avacopan is associated with high remission rates and low relapse in ANCA-associated vasculitis Avacopan shows high remission rates for ANCA-associated vasculitis
This systematic review and meta-analysis of 71 studies indicates that avacopan is associated with an 87% remission rate at 6 months and a 93…
New data shows avacopan helps many patients with ANCA-associated vasculitis reach remission while reducing the need for steroid use.
medRxiv Jun 18, 2026